Updated:
Relief Therapeutics Holding AG
Relief Therapeutics Holding AG is a Swiss biopharmaceutical company focused on rare disease therapeutics, publicly traded on the SIX Swiss Exchange.
Relief Therapeutics Holding AG
Relief Therapeutics Holding AG is a publicly traded biopharmaceutical company listed on the SIX Swiss Exchange. Its founding and wealth origin remain undisclosed in public records; the firm operates as a single-purpose drug developer, not a family office. The company focuses on rare disease therapeutics, with a pipeline that includes treatments for genetic and metabolic disorders. The company's strategy centers on in-house R&D and potential partnerships for late-stage clinical development. Confirmed asset classes include only biopharmaceutical drug development; no disclosed investments in other sectors or financial assets exist. Geographic footprint is primarily Swiss, with potential clinical operations in Europe and North America per standard industry practice. No public data on total deployment, team size, or professionals exists for Relief Therapeutics. The firm maintains no known adjacent vehicles such as philanthropic foundations or real-asset arms. No recent operational events from the last 24 months are available in public record. The structural differentiator for Relief Therapeutics is its public listing—a governance and capital structure distinct from private family offices or venture capital firms. This means its financial disclosures are subject to Swiss stock exchange regulations, and its mandate is solely drug development rather than wealth management.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Geneva
Corporate office
Geneva, Switzerland
Frequently asked questions
Is Relief Therapeutics a family office?
No—Relief Therapeutics is a publicly traded biopharmaceutical company on the SIX Swiss Exchange. It operates as a drug developer, not as a wealth management or family office entity.
What types of diseases does Relief Therapeutics target?
The company focuses on rare and genetic diseases, including metabolic disorders.
Where is Relief Therapeutics headquartered?
The firm is based in Geneva, Switzerland, per public records.
Who leads investment decisions at Relief Therapeutics?
No named principals are publicly disclosed for investment decisions; the company is led by a board and management team, but specific names are not available in the provided sources.
Is Relief Therapeutics involved in direct deals or fund commitments?
The company's public disclosures do not indicate involvement in fund commitments or direct deals outside its drug development pipeline.
What is the ownership structure of Relief Therapeutics?
As a publicly traded company, its ownership is distributed among shareholders who trade on the SIX Swiss Exchange.
Does Relief Therapeutics have any known philanthropic structures?
No public information is available regarding philanthropic foundations or structures associated with Relief Therapeutics.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: